As of June 13, 2025, Acer Therapeutics Inc (ACER) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Acer Therapeutics Inc's Forward P/E to Peers
To better understand Acer Therapeutics Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Acer Therapeutics Inc (ACER) | - |
| Catalent Inc (CTLT) | 55.81 |
| Eli Lilly and Co (LLY) | 36.82 |
| Zoetis Inc (ZTS) | 26.35 |
| Elanco Animal Health Inc (ELAN) | 16.49 |
| Johnson & Johnson (JNJ) | 14.62 |
Compared to its competitors, Acer Therapeutics Inc's Forward P/E is difficult to compare due to insufficient data.